Online citations, reference lists, and bibliographies.
← Back to Search

Ipilimumab In Combination With Paclitaxel And Carboplatin As First-line Treatment In Stage IIIB/IV Non-small-cell Lung Cancer: Results From A Randomized, Double-blind, Multicenter Phase II Study.

T. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlési, R. Chacko, M. Sebastian, J. W. Neal, H. Lu, J. Cuillerot, M. Reck
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE Ipilimumab, which is an anti-cytotoxic T-cell lymphocyte-4 monoclonal antibody, showed a survival benefit in melanoma with adverse events (AEs) managed by protocol-defined guidelines. A phase II study in lung cancer assessed the activity of ipilimumab plus paclitaxel and carboplatin. PATIENTS AND METHODS Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for ≤ 18 weeks (induction). Eligible patients continued ipilimumab or placebo every 12 weeks as maintenance therapy. Response was assessed by using immune-related response criteria and modified WHO criteria. The primary end point was immune-related progression-free survival (irPFS). Other end points were progression-free survival (PFS), best overall response rate (BORR), immune-related BORR (irBORR), overall survival (OS), and safety. RESULTS The study met its primary end point of improved irPFS for phased ipilimumab versus the control (hazard ratio [HR], 0.72; P = .05), but not for concurrent ipilimumab (HR, 0.81; P = .13). Phased ipilimumab also improved PFS according to modified WHO criteria (HR, 0.69; P = .02). Phased ipilimumab, concurrent ipilimumab, and control treatments were associated with a median irPFS of 5.7, 5.5, and 4.6 months, respectively, a median PFS of 5.1, 4.1, and 4.2 months, respectively, an irBORR of 32%, 21% and 18%, respectively, a BORR of 32%, 21% and 14%, respectively, and a median OS of 12.2, 9.7, and 8.3 months. Overall rates of grade 3 and 4 immune-related AEs were 15%, 20%, and 6% for phased ipilimumab, concurrent ipilimumab, and the control, respectively. Two patients (concurrent, one patient; control, one patient) died from treatment-related toxicity. CONCLUSION Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC.
This paper references
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1016/1074-7613(94)90071-X
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
10.1016/S0022-5223(03)00707-4
Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.
R. Merritt (2003)
10.1172/JCI40269
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
R. Ramakrishnan (2010)
10.1038/nri2216
Immunological aspects of cancer chemotherapy
L. Zitvogel (2008)
10.1158/1078-0432.CCR-06-2318
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1158/0008-5472.CAN-08-0427
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
L. Apetoh (2008)
10.2147/CE.S7418
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
S. Haslam (2007)
10.1177/1758834010386402
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence
F. Lee (2011)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in extensive disease-small cell lung cancer (ED-SCLC): Results from a phase 2 trial
M Reck (1365)
10.1089/cbr.2010.0865
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
A. Tarhini (2010)
10.1200/JCO.2007.25.18_SUPPL.7554
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste (2007)
10.1093/annonc/mdn745
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
M. Socinski (2009)
10.1097/JTO.0b013e3181f7c6d4
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
G. Scagliotti (2011)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1634/THEONCOLOGIST.12-6-713
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
M. Cohen (2007)
10.1158/1078-0432.CCR-05-2013
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
S. Antonia (2006)
Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide or gemcitabine in murine models
G Masters (2009)
10.1016/j.athoracsur.2008.10.067
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.
E. Ruffini (2009)
10.1016/s1525-7304(11)70592-7
Paclitaxel 175 mg/m2 plus carboplatin versus paclitaxel 225 mg/m2 plus carboplatin for advanced non small-cell lung cancer (NSCLC).
(2000)
10.1158/1078-0432.CCR-06-1974
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
D. O'Mahony (2007)
10.1245/ASO.2005.03.536
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1158/1078-0432.CCR-08-2424
Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
O. Klein (2009)
10.1038/sj.bjc.6602934
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
K. Hiraoka (2006)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Predominant infiltration of macrophages and CD 8 (  ) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall
E Ruffini (2008)
10.1093/BIOMET/26.4.404
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
C. J. Clopper (1934)
10.1053/j.seminoncol.2010.09.007
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
10.1111/j.1349-7006.2003.tb01392.x
CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers
O. Wakabayashi (2003)
10.1007/s10637-009-9376-8
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
E. Hersh (2009)
10.1056/NEJMOA011954
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
J. Schiller (2002)
10.1097/PPO.0b013e3181eb5066
Chemoimmunotherapy
Leisha A. Emens (2010)
10.1016/S1470-2045(09)70334-1
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1053/j.seminoncol.2010.09.015
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
A. Hoos (2010)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1016/j.coi.2008.05.007
Immunogenic cancer cell death: a key-lock paradigm.
A. Tesnière (2008)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1200/JCO.2006.09.7097
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
J. Vansteenkiste (2007)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1200/JCO.2007.14.5466
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
M. Reck (2009)
10.2307/2530286
A Confidence Interval for the Median Survival Time
R. Brookmeyer (1982)
Paclitaxel (175 mg/m 2 ) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m ) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
P. Kosmidis (2000)
10.3816/CLC.2010.n.029
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
R. Kelly (2010)
10.2217/imt.10.21
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
D. Page (2010)
10.1093/annonc/mdq013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
10.4049/jimmunol.170.10.4905
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
A. Nowak (2003)
10.1111/j.1600-0560.2010.01506.x
The biologic importance of tumor‐infiltrating lymphocytes
F. S. Hodi (2010)
10.1620/TJEM.191.113
Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis.
M. Mori (2000)
10.1002/cncr.23712
Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer
O. Kawai (2008)
10.1097/PAI.0b013e3181b6a741
A High Number of CD8+ T Cells Infiltrated in NSCLC Tissues is Associated With a Favorable Prognosis
Xuewei Zhuang (2010)
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
10.1158/1078-0432.CCR-08-0133
Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer
K. Al-Shibli (2008)
10.1056/NEJMOA061884
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
10.1097/CJI.0b013e31815b69c8
Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs
P. Correale (2008)
10.1200/JCO.2005.13.011
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
C. Butts (2005)



This paper is referenced by
10.1016/S1877-1203(12)70320-8
Les avancées de l'immunothérapie dans les cancers bronchiques non à petites cellules
C. Leduc (2012)
10.1016/j.lungcan.2015.02.007
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
M. Howell (2015)
10.1007/978-3-319-45865-6_27
Tumor Immunology and Immunotherapy in Cancer Patients
R. Marks (2016)
10.1530/ERC-17-0003
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.
Jue Shi (2017)
10.2217/fon-2016-0385
Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Paul Letendre (2017)
10.1159/000436998
Immunotherapy of Melanoma.
A. Snyder (2015)
10.1007/s00262-017-2039-2
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
Erna-Elise Paulsen (2017)
10.1158/2326-6066.CIR-13-0211
Assessment of MAGE-A Expression in Resected Non–Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of EGFR and KRAS
M. Ayyoub (2014)
10.1016/j.jtho.2016.05.027
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
F. Facchinetti (2016)
10.1158/0008-5472.CAN-12-3932
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.
J. Aerts (2013)
10.1159/000437186
Combinations Therapies.
N. Reinmuth (2015)
10.1055/s-0042-105063
Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie
N. Reinmuth (2015)
10.21037/jtd.2017.08.68
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
P. Pastina (2017)
10.3978/j.issn.2072-1439.2013.08.52
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
P. Savas (2013)
Years of Progress in the Systemic Therapy of Non – Small Cell Lung Cancer
H. Wakelee (2014)
10.1055/s-0040-1710077
Immunotherapy in Advanced Non-Small Cell Lung Cancer.
J. Huang (2020)
10.1007/978-3-030-31171-1_2
Response Evaluations for Precision Cancer Therapy and Immunotherapy
M. Nishino (2020)
10.1007/s10555-015-9566-0
Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
D. Zhang (2015)
10.1007/s12055-017-0566-2
Immunotherapy for thoracic malignancies
J. Dozier (2017)
10.1038/nrclinonc.2016.148
Lung cancer: First-line immunotherapy in lung cancer — taking the first step
S. Liu (2016)
10.1146/annurev-immunol-032414-112049
Coinhibitory Pathways in Immunotherapy for Cancer.
S. Baumeister (2016)
10.1016/j.soc.2016.02.011
Targeted Therapy and Immunotherapy for Lung Cancer.
E. C. Naylor (2016)
10.1201/B15944-16
Immunotherapy: CTLA4, PD-1, PD-L1, IL-18, and IL-21
Patrick M. Forde (2013)
10.1016/B978-0-12-374279-7.17024-9
Combining Immunotherapies with Standard Therapies in the Treatment of Cancer
J. Pitt (2016)
10.1007/s00432-017-2546-8
Can checkpoint inhibitor therapy improve response to chemotherapy?
M. Kirchberger (2017)
10.1016/j.critrevonc.2015.08.015
Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.
O. Abdel-Rahman (2016)
10.1158/2326-6066.CIR-13-0078
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
J. Brahmer (2013)
10.1097/PPO.0000000000000302
Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond
Matthew C Dallos (2018)
10.1007/s13665-014-0072-6
Immunotherapy for non-small-cell lung cancer: current approaches
É. Quoix (2014)
10.1038/bjc.2016.166
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
Vishwajith Sridharan (2016)
10.2217/fon-2016-0086
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
M. Decatris (2016)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar